International Journal of Alzheimer’s Disease / 2013 / Article / Tab 5

Research Article

Preferential Selectivity of Inhibitors with Human Tau Protein Kinase Gsk3 Elucidates Their Potential Roles for Off-Target Alzheimer’s Therapy

Table 5

Interaction of binding site residues amongst the 10 tau kinases with ATP.

GSK3βCDK5P38ERK1/2JNKCK1dDYRK1AAKTPKAPKCATP binding site conservation across the 10 kinases

#I 62 I10 V31 I 31 I 70 I 15- I 165- L156 L49 L345 I/V/L
#G 63 G11 G32 G32 >6 G71 G16 G166 G157 G50 G346 G-well conserved
#N 64 S33 E33 >6 K167 K158- T51 K347 Not conserved
#G 65 G34 Y36 G168 G159 G52 G348 >6 Not conserved
#S 66 A35 S169 >6 S53 S349 Not conserved
#F 67 Y36 F20 F170 >6 F161 F54 Not conserved
#V 70 V18- V39 V39 V78 >6 I 23 V173 >6 V164 V57 V353 V/I
#A 83 A31 A52 A52 A91 A 36 A186 A177 A70 A366 A-well conserved
#K 85 K33 K54- K54- K93 K38 K188 I179 K72- K368- K-well conserved
#E 97 E51 >6 E72 E71 E111 E52 E203 E198 E91 E387 E-well conserved
#V 110 V64 >6 I85 >6 I84 >6 I124 >6 P66 >6 V222 T211 V104 T401 V/I/P/T
#L 132 F80 M107 Q105- M146- M82- F238 M227 M120 M417 F/Q/M
#D 133 E81- P108- D106- E147 E-83- E239- E228- E121- E418- D/E-well conserved
#Y 134 F82 F109 L107 L148 L84 M240 Y229 Y122 Y419 F/L/M/Y
#V 135 C83- M110- M108- M149- L85- L241- A230- V123- V420- C/M/L/A/V
#T 138 D86- D113- D111- N152- S88- N244 E 234- E127- D424- D/N/S/E
#R 141 K89 K116 K 114 Q 155 D 91 D247 F237 S130 Y427 >6 R/K/Q/D/F/S/Y
#Q 185 Q130- G 154 S153- S193 D132 E291 E278- E170 D467- Q/G/S/D/E
#N 186 N131 N155 >6 N154 N194 N133 N292 N279 N171 N468 N-well conserved
#L 188 L133 A157 L156 >6 V196 >6 L135 L294 >6 M281 L173 M470 L/A/V/M
#C 199 A143 L167 >6 C166 L206 I148 V306 T291 T183 A480 C/A/L/I/V/T
#D 200 N144 D168 D167 D207 D149 D307- D292 D184 D481- D-well conserved

22161916151818212218Number of interacting residues with ATP within 6 

Indicates residue type and number; *indicates distances in Angstroms.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.